研究者業績

石川 等真

イシカワトモ マサ  (ishikawa tomomasa)

基本情報

所属
藤田医科大学 医学部・内科学 助教
学位
博士(医学)(藤田保健衛生大学)

J-GLOBAL ID
201501011570862691
researchmap会員ID
7000012814

論文

 8
  • Yoshiki Niimi, Shinji Ito, Kenichiro Murate, Seiko Hirota, Chika Hikichi, Tomomasa Ishikawa, Toshiki Maeda, Ryunosuke Nagao, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Tatsuro Mutoh
    JOURNAL OF THE NEUROLOGICAL SCIENCES 377 174-178 2017年6月  査読有り
    Background: Although single-photon emission computerized tomography of the dopamine transporter (DATSPECT) is useful for diagnosing parkinsonian syndrome, its applicability toward the early phase of Parkinson's disease remains unknown. Methods: We enrolled 32 patients showing parkinsonism with normal cardiac I-123-metaiodobenzylguanidine (MIBG) uptake and abnormal DAT-SPECT findings among 84 consecutive patients with parkinsonism. We divided these patients into two groups (group 1: Parkinson's disease, group 2: corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy), and compared their clinical characteristics, specific binding ratios, and striatal asymmetry indexes on DAT-SPECT examinations. Results: The striatal asymmetry indexes were significantly lower in group 1 than in group 2 (p < 0.05), but there were no differences in the specific binding ratios between the two groups. Conclusion: The combined use of striatal asymmetry index on DAT-SPEC' and cardiac MIBG scintigraphy might offer useful clues for the differential diagnosis of the early phase Parkinson's disease from other parkinsonian syndromes. (C) 2017 Elsevier B.V. All rights reserved.
  • Tomomasa Ishikawa, Kunihiko Asakura, Yasuaki Mizutani, Akihiro Ueda, Ken-Ichiro Murate, Chika Hikichi, Sayuri Shima, Madoka Kizawa, Masako Komori, Kazuhiro Murayama, Hiroshi Toyama, Shinji Ito, Tatsuro Mutoh
    MUSCLE & NERVE 55(4) 483-489 2017年4月  査読有り
    Introduction: To visualize peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), we used MR imaging. We also quantified the volumes of the brachial and lumbar plexus and their nerve roots. Methods: Thirteen patients with CIDP and 12 healthy volunteers were enrolled. Whole- body MR neurography based on diffusionweighted whole- body imaging with background body signal suppression ( DWIBS) was performed. Peripheral nerve volumes were calculated from serial axial MR images. Results: The peripheral nervous system was visualized with 3-dimensional reconstruction. Volumes ranged from 8.7 to 49.5 cm(3)/m(2) in the brachial plexus and nerve roots and from 10.2 to 53.5 cm(3)/m(2) in the lumbar plexus and nerve roots. Patients with CIDP had significantly larger volumes than controls ( P < 0.05), and volume was positively correlated with disease duration. Conclusions: MR neurography and the measurement of peripheral nerve volume are useful for diagnosing and assessing CIDP.
  • Shinji Ito, Akihiro Ueda, Kenichiro Murate, Seiko Hirota, Takao Fukui, Tomomasa Ishikawa, Sayuri Shima, Chika Hikichi, Yasuaki Mizutani, Madoka Kizawa, Kunihiko Asakura, Tatsuro Mutoh
    JOURNAL OF THE NEUROLOGICAL SCIENCES 368 344-348 2016年9月  査読有り
    Objective: Acute multifocal embolic infarction (AMEI) is conventionally caused by etiologies such as cardioembolism due to atrial fibrillation (AO, but can also be caused by serious underlying diseases such as cancer. We characterized cancer-related AMEI and identified useful indicators for cancer-associated strokes. Methods: A retrospective analysis was performed on 35 patients with Af-related AMEI and 35 patients with cancer -related AMEI selected from 1235 consecutive patients with acute infarcts. All patients received diffusion weighted magnetic resonance (MR) imaging. Cerebral MR angiography, carotid and cardiac ultrasonography, electrocardiogram-monitoring and whole body computed tomography were also performed on these patients. D-dimer levels were evaluated on admission, and were measured during the sub-acute phase in 19 of the patients with Af and 27 of the patients with cancer. Results: Acute phase D-dimer levels were significantly higher in patients with cancer than in patients with Af alone. The cut-off D-dimer value to identify cancer-associated infarcts was 2.0 mu g/mL. D-dimer levels during the sub-acute phase remained elevated in the cancer patients. Conclusions: We may differentiate cancer-associated AMEI from Af using a D-dimer level >= 2.0 mu g/mL, which does not decrease during the sub-acute phase. (C) 2016 Elsevier B.V. All rights reserved.
  • Yasuaki Mizutani, Shinji Ito, Kenichiro Murate, Seiko Hirota, Takao Fukui, Chika Hikichi, Tomomasa Ishikawa, Sayuri Shima, Aldhiro Ueda, Madoka Kizawa, Kunihiko Asakura, Tatsuro Mutoh
    JOURNAL OF THE NEUROLOGICAL SCIENCES 359(1-2) 236-240 2015年12月  査読有り
    Background: Although most patients with Parkinson's disease (PD) show decreased cardiac I-123-metaiodobenzylguanidine (MIBG) uptake, some exhibit normal uptake. We evaluated the clinical characteristics of such patients. Methods: We enrolled 154 non-demented patients showing parkinsonism with normal cardiac MIBG uptake and had been clinically followed up during 29.9 +/- 27.6 months. We defined the patients who did not fit the exclusion criteria for PD and demonstrated >= 30% reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score after anti-Parkinson agent administration as probable PD. We compared clinical characteristics and the cardiac MIBG heart-to-mediastinum (H/M) ratio between the probable PD group (N = 37) and other groups (N = 117). Results: The probable PD group showed significantly higher UPDRS motor scores and greater incidence of tremor/rigidity than those of other groups. In addition, they showed a significantly lower cardiac MIBG HIM ratio in the delayed phase (delayed, p < 0.0001). Washout-rate (WR) was significantly higher in probable PD cases (p < 0.0001). Among 16 probable PD patients undergoing serial cardiac MIBG scintigraphy, the delayed phase cardiac MIBG H/M ratio showed a significant decrease and WR significantly increased during follow-up periods. Conclusions: An increase in WR and lower delayed phase cardiac MIBG uptake were found to be characteristics of such patients. (C) 2015 Elsevier B.V. All rights reserved.
  • Takao Fukui, Kunihiko Asakura, Chika Hikichi, Tomomasa IshikaWa, Rie Murai, Seiko Hirota, Ken-ichiro Murate, MadOko Kizawa, Akihiro Ueda, Shinji Ito, Tatsuro Mutoh
    TOXICOLOGY 331 112-118 2015年5月  査読有り
    Clioquinol is considered to be a causative agent of subacute myelo-optico neuropathy (SMON), although the pathogenesis of SMON is yet to be elucidated. We have previously shown that clioquinol inhibits nerve growth factor (NGF)-induced Trk autophosphorylation in PC12 cells transformed with human Trk cDNA. To explore the further mechanism of neuronal damage by clioquinol, we evaluated the acetylation status of histones in PC12 cells. Clioquinol reduced the level of histone acetylation, and the histone deacetylase (HDAC) inhibitor Trichostatin A upregulated acetylated histones and prevented the neuronal cell damage caused by clioquinol. In addition, treatment with HDAC inhibitor decreased neurite retraction and restored the inhibition of NGF-induced Trk autophosphorylation by clioquinol. Thus, clioquinol induced neuronal cell death via deacetylation of histones, and HDAC inhibitor alleviates the neurotoxicity of clioquinol. Clioquinol is now used as a potential medicine for malignancies and neurodegenerative diseases. Therefore, HDAC inhibitors can be used as a candidate medicine for the prevention of its side effects on neuronal cells. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

MISC

 2

講演・口頭発表等

 62